🔴 Tscan Therapeutics is trading 11.42% down with no confirmed catalyst identified

Tscan Therapeutics is trading at $0.18, down 11.42%, with no confirmed catalyst identified for the October 26 decline.

• No clear company-specific announcement explaining the decline was found.
• A proxy filing proposes a potential reverse stock split to address Nasdaq’s minimum bid-price requirement, but available reporting does not link it directly to the move.
• The broader market is higher; October 26 trading volume was not available in the provided data.